GENNEX LABORATORIES
|
The Current P/E Ratio of GENNEX LABORATORIES is 14.31.
| Share Price | ₹12.2 | Aug 25,2026 |
| Market Cap | ₹295.1 Cr | |
| Earnings-TTM | ₹20.6 Cr | TTM-Consolidated Results |
| Price/Earnings | 14.31x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GENNEX LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹295.1 Cr] as on Aug 25,2026
(/) Earnings [ ₹20.6 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 14.31x ]
Thus, for GENNEX LABORATORIES , the investors are currently willing to pay 14.31 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GENNEX LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GENNEX LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of GENNEX LABORATORIES
PE Ratio Performance Analysis for GENNEX LABORATORIES
- GENNEX LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.31x.
- GENNEX LABORATORIES 's operated at median p/e ratio of 16x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GENNEX LABORATORIES 's p/e ratio peaked in Mar2024 at 31.6x.
- GENNEX LABORATORIES 's p/e ratio hit its five-year low in Mar2021 of 11.69x.
How does GENNEX LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GENNEX LABORATORIES | 20.63 | 14.31 | 295.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.79 | 459,952.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 78.78 | 230,427.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.80 | 187,141.0 |
| CIPLA LTD | 3,364.84 | 34.09 | 114,715.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.37 | 99,409.9 |
| MANKIND PHARMA LTD | 2,055.11 | 47.57 | 97,756.1 |
| LUPIN LTD | 5,551.01 | 17.92 | 99,448.6 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.09 | 112,718.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 24.85 | 92,247.5 |
| LAURUS LABS LTD | 1,090.76 | 92.38 | 100,768.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GENNEX LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 14.31x |
| Max industry PE | 92.38x |
| Median industry PE | 34.09x |
| Average industry PE | 44.63x |
You may also like the below Video Courses